SciSparc Ltd. (SPRC)
NASDAQ: SPRC · Real-Time Price · USD
0.223
-0.010 (-4.20%)
Nov 4, 2024, 4:00 PM EST - Market closed
SciSparc Employees
SciSparc had 3 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
3
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$959,667
Profits / Employee
-$1,707,333
Market Cap
726.33K
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Aditxt | 47 |
| TC Biopharm (Holdings) | 41 |
| LogicMark | 27 |
| Elevai Labs | 18 |
| Catheter Precision | 14 |
| Cyclacel Pharmaceuticals | 12 |
| Revelation Biosciences | 9 |
| PainReform | 7 |
SPRC News
- 5 weeks ago - SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment - GlobeNewsWire
- 5 weeks ago - SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX - GlobeNewsWire
- 6 weeks ago - SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment - GlobeNewsWire
- 6 weeks ago - SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment - GlobeNewsWire
- 7 weeks ago - SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy - GlobeNewsWire
- 7 weeks ago - SciSparc Advances $1.85 million Loan to AutoMax, Following AutoMax's Direct Import Agreement with Major Chinese Vehicle Manufacturer - GlobeNewsWire
- 2 months ago - SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment - GlobeNewsWire
- 2 months ago - SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination - GlobeNewsWire